The fate of FTC v. Actavis, Inc. in the biosimilar context - does and should the FTC v. Actavis decision apply to reverse patent settlements between brand drug and biosimilar manufacturers?
Ho, Nicola Gabrielle
(2022)
The fate of FTC v. Actavis, Inc. in the biosimilar context - does and should the FTC v. Actavis decision apply to reverse patent settlements between brand drug and biosimilar manufacturers?
Biotechnology Law Report, 41 (4).
194 - 199.
ISSN 0730-031X
| Item Type | Article |
|---|---|
| Keywords | Actavis,antitrust,bio-similars,brand-drugs,generics,intellectual property,reverse patent settlements |
| Departments | LSE |
| DOI | 10.1089/blr.2022.29274.nho |
| Date Deposited | 13 Sep 2022 09:33 |
| URI | https://researchonline.lse.ac.uk/id/eprint/116601 |